Literature DB >> 19913072

Emotional management and 5-HT2A receptor gene variance in patients with schizophrenia.

Chi-Hsuan Lo1, Guochuan E Tsai, Chun-Hui Liao, Ming-Yu Wang, Jane Pei-Chen Chang, Hui-Chun Tsuang, Hsien-Yuan Lane.   

Abstract

Individuals with schizophrenia exhibit impaired social cognitive functions, particularly emotion management. Emotion management may be partially regulated by the serotoninergic system; the -1438 A/G polymorphism in the promoter region of the 5-HT2A gene can modulate 5-HT2A activity and is linked to certain emotional traits and anger- and aggression-related behaviors. The current study aimed to investigate whether this 5-HT2A genetic variance is associated with social cognitive function, particularly the management of emotions. One hundred and fifteen patients with chronic schizophrenia were stabilized with an optimal-dose of antipsychotic treatment. All were genotyped for the -1438 A/G polymorphism and assessed with symptom rating scales, neurocognitive instruments, and the "Managing Emotions" section of Mayer-Salovey-Caruso Emotional Intelligence Test (MSCEIT). Multiple regression showed that patients with the A/G genotype performed better than those with G/G in managing emotion (p=0.018) but did not differ from those with the A/A genotype. Regarding the two subtasks of the Managing Emotions section, the A/G heterozygotes also performed better than the G/G homozygotes in the emotion management (p=0.026) and emotional relations (p=0.027) subtasks. The results suggest that variability in the 5-HT2A gene may influence emotion management in patients with schizophrenia. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19913072     DOI: 10.1016/j.biopsycho.2009.11.002

Source DB:  PubMed          Journal:  Biol Psychol        ISSN: 0301-0511            Impact factor:   3.251


  8 in total

Review 1.  Efficacy of typical and atypical antipsychotic medication on hostility in patients with psychosis-spectrum disorders: a review and meta-analysis.

Authors:  Margo D M Faay; Pál Czobor; Iris E C Sommer
Journal:  Neuropsychopharmacology       Date:  2018-07-23       Impact factor: 7.853

2.  Structural neurobiological correlates of Mayer-Salovery-Caruso Emotional Intelligence Test performance in early course schizophrenia.

Authors:  Jessica A Wojtalik; Shaun M Eack; Matcheri S Keshavan
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-10-02       Impact factor: 5.067

3.  MET and AKT genetic influence on facial emotion perception.

Authors:  Ming-Teng Lin; Kuo-Hao Huang; Chieh-Liang Huang; Yu-Jhen Huang; Guochuan E Tsai; Hsien-Yuan Lane
Journal:  PLoS One       Date:  2012-04-27       Impact factor: 3.240

4.  PICK1 Genetic Variation and Cognitive Function in Patients with Schizophrenia.

Authors:  Yi-Ting Chen; Chieh-Hsin Lin; Chiung-Hsien Huang; Wen-Miin Liang; Hsien-Yuan Lane
Journal:  Sci Rep       Date:  2017-05-15       Impact factor: 4.379

5.  Gender differences measured by the MATRICS consensus cognitive battery in chronic schizophrenia patients.

Authors:  Baohua Zhang; Mei Han; Shuping Tan; Fu De Yang; Yunlong Tan; Shurong Jiang; Xiangyang Zhang; Xu-Feng Huang
Journal:  Sci Rep       Date:  2017-09-19       Impact factor: 4.379

6.  Genetic Effects of DISC1 and G72 (DAOA) on Visual Learning of Patients with Schizophrenia.

Authors:  Jane Pei-Chen Chang; Kuo-Hao Huang; Hsien-Yuan Lane; Chieh-Hsin Lin
Journal:  Neuropsychiatr Dis Treat       Date:  2020-03-20       Impact factor: 2.570

7.  Association Between Lack of Insight and Prefrontal Serotonin Transporter Availability in Antipsychotic-Free Patients with Schizophrenia: A High-Resolution PET Study with [11C]DASB.

Authors:  Jeong-Hee Kim; Young-Don Son; Hang-Keun Kim; Jong-Hoon Kim
Journal:  Neuropsychiatr Dis Treat       Date:  2021-10-21       Impact factor: 2.570

8.  Polymorphism in the LASP1 gene promoter region alters cognitive functions of patients with schizophrenia.

Authors:  Chieh-Hsin Lin; Sheng Yang; Yu-Jhen Huang; Hsien-Yuan Lane
Journal:  Sci Rep       Date:  2019-12-11       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.